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Hillary F Berman1, Sara Yee Tartof1,2, Joice N Reis3, Mitermayer G Reis3 and Lee W Riley1*Abstract
Background: Group A streptococcus (GAS) causes invasive disease, superficial disease, and can asymptomatically
colonize humans. Superantigens are one virulence factor found in GAS. Previous studies found associations
between the genes that encode superantigens and emm type of GAS. It is unknown if these associations are due to
underlying biological factors that limit the distribution of superantigens or, alternatively, if these associations are
due to the expansion of local GAS linages where these studies took place. To further address this question we
screened GAS isolates collected from Salvador, Brazil for 11 known superantigen genes.
Methods: Seventy-seven GAS isolates were screened by PCR for superantigen genes. These superantigen genes
were speA, speC, speG, speH, speI, speJ, speK, speL, speM, ssa, and smeZ. We used Fisher’s two-sided exact test to
identify associations between superantigens and GAS emm type. We then compared our results to previous reports
of superantigen prevalence and superantigen association with emm type.
Results: In our collection we found several emm type and superantigen genotype combinations that have
previously been reported in isolates from Europe and Australia. We also found that speA was significantly associated
with emm type 1, and that speC was significantly associated with emm type 12.
Conclusions: Our study reports superantigen genotypes of GAS from a region of the world that is lacking this
information. We found evidence of common GAS superantigen genotypes that are spread worldwide as well as
novel superantigen genotypes that, so far, are unique to Brazil.
Keywords: Streptococcus pyogenes, Streptococcal superantigens, Group A streptococcus, Emm typesBackground
Streptococcus pyogenes (Group A Streptococcus, or GAS)
is a Gram positive bacterium that causes a wide spectrum
of clinical manifestations including pharyngitis, skin infec-
tions, necrotizing fasciitis, and streptococcal toxic shock
syndrome [1]. GAS harbors many virulence factors includ-
ing superantigens [1].
Superantigens are bacterial exotoxins that are able to
activate large numbers of T cells [1-3]. There are eleven
known superantigens found in S. pyogenes: SpeA, SpeC,
SpeG, SpeH, SpeI, SpeJ, SpeK, SpeL, SpeM, SSA, and
SmeZ [4]. Superantigen genotype varies by emm type
and the region of the world in which the isolate was col-
lected [5,6]. An area of active research is whether these
associations are due to factors that limit the distribution* Correspondence: lwriley@berkeley.edu
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reproduction in any medium, provided the orof superantigens or are due to the expansion of local
GAS linages [7]. To further address this question we
studied a collection of GAS isolates from Brazil. Previous
studies of superantigens in GAS isolates from this region
of the world are limited and none of these studies have re-
ported the genotypes of all eleven superantigens [8].
Some superantigens are encoded by genes located in
the prophage region of the GAS genome. Others are
encoded by genes located outside of this region and are
considered to be chromosomally encoded [7,9,10]. The
SpeA, speC, SpeH, speI, speK, speL, speM and ssa genes
have been found within prophages in streptococcal iso-
lates [4,7,11]. The speG, SpeJ, and smeZ genes are con-
sidered to be encoded chromosomally [9,12].
The aim of this project was to determine if associa-
tions between superantigens, superantigen genotypes,
and emm types that have been reported elsewhere were
also found in our collection of Group A streptococcusl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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were collected as part of a previous study of Group A
Streptococcus in children with and without pharyngitis
[13,14]. From this previously published study we selected
all isolates of the two most common emm types (emm 1
and emm 12) and the emm type with the strongest asso-
ciation with pharyngitis (emm 66) to genotype [13].
Methods
Isolate collection and emm typing
S. pyogenes isolates were collected and emm typing was
conducted as part of a separate cross-sectional study de-
tailed elsewhere [13,14]. Briefly, isolates were collected
from three hospital clinics in Salvador, Brazil. Patients
between the ages of three and fifteen were recruited
from the middle of April 2007 to end of October 2008
[13,14]. As described in previous publications, Institu-
tional Review Board (IRB) approval was obtained from all
hospitals, the Comissão Nacional de Ética em Pesquisa
(Conep) (National Bioethics Commission of Brazil), the
Comitê de Ética em Pesquisa-Centro de Pesquisa Gonçalo
Moniz-Fiocruz (Ethics Committee for Research - Fiocruz),
and the University of California, Berkeley Committee for
the Protection of Human Subjects [13,14]. As previously
described consent was obtained from parents or guardians
and verbal consent was obtained from children [13,14].
Isolates were collected from children who had pharyngitis
(strep throat) and those who were asymptomatic carriers
of GAS. Emm typing of all isolates was performed as de-
scribed by the Center for Disease Control and Prevention
(CDC) protocol http://www.cdc.gov/ncidod/ biotech/strep/
protocol_emm-type.htm.Table 1 Primers used
Gene Forward primer (5′ to 3′) Reverse p
speA1-3,6 [15] 5′-GGACTAACAATCTCGCAAGAGG-3′ 5′-TTACTT
speA4,5 [15] 5′-GCTAACAACCTCACAAGAAG -3′ 5′-TGCTTG
speC [15] 5′-GATTTCTACTATTTCACC-3′ 5′-AAATA
speG [15] 5′-CTTATGCAGATGAAAATTTAAAAGATT-3′ 5′-AAAGC
speI [15] 5′-ATGAGTAGTGTGGGAGTTATTAA-3′ 5′-ATGAA
speJ [15] 5′-ATCTTATTTAGTCCAAAGGTAAAT-3′ 5′-GTGAA
smeZ [15] 5′-TTGGATTAGAAGTAGATAA-3′ 5′-TTGAA
ssa [15] 5′-AGTCAGCCTGACCCTACTCCA-3′ 5′-TAAGG
speH [6] 5′-TTGGATCCAATTCTTATAATACAACC-3′ 5′-CCACT
speJ [6] 5′-CTATGGTGGAATTACACC-3′ 5′-CATGTT
speK [6] 5′-GCGGATCCGATACGTACAATACAAATG-3′ 5′-GCGAA
speL [6] 5′-GCAGCCATATGGAAGAGACTATTCCTCTTAAG
GATATATACTCTC-3′
5′-GGGGA
speM [6] 5′-GCAGCCATATGTTTTCAGATGCTGTGTTGG-3′ 5′-GGGGA
speB [6] 5′-GGATCCCAACCAGTTGTTAAATCTCT-3′ 5′-AACGT
All primer sequences shown here have previously been published by Maripuu et alWe selected the two most common emm types (emm 1;
n = 25 and emm 12; n = 40) as well as the emm type with
strongest association with pharyngitis (emm 66; n = 12) to
analyze for superantigen genes. For the purposes of this
analysis the emm 1.25 isolate (n = 1) was included with
emm 1.
Superantigen identification by PCR
Superantigen genes were identified by PCR using prim-
ers previously published by Maripuu et al. or Commons
et al. [6,15] (Table 1). The Commons et al. primers were
used to identify speB (a positive control for DNA qual-
ity), speJ, speK, speH, speL, and speM. The Maripuu
et al. primers were used to identify speA, speC, speG,
speI, ssa, and smeZ. Each 20 μl PCR mixture contained
1 U of taq DNA polymerase (New England Biolabs,
Ipswich, MA), 0.25 mM DNTPs (New England Biolabs,
Ipswich, MA), 1X ThermoPol buffer (New England Bio-
labs, Ipswich, MA), 1 μl template DNA, and 1 nanomole
of the forward and reverse primer. Template DNA was
extracted with the Qiagen DNEasy kit as previously de-
scribed [13]. The cycling program for the Commons
et al. primers was as follows: 2 minutes at 95°C, 35 cycles
of 30 seconds at 94°C, 30 seconds at 50°C, 60 seconds at
72°C, and a final extension for 2 minutes at 72°C. The
cycling program used for Maripuu et al. was as follows:
5 minutes at 94°C, 25 cycles of 30 seconds at 94°C,
30 seconds at primer specific annealing temperature,
60 seconds at 72°C, and a final extension of 7 minutes at
72°C. As a positive control for each superantigen gene
PCR, we used the DNA of an isolate known to contain the
relevant superantigen gene. We were unable to amplifyrimer (5′ to 3′) Annealing
temp. °C
Product
size (bp)
GGTTGTTAGGTAGACTTC-3′ 54 696
AGTCAAGCGTCTC-3′ 53 659
TCTGATCTAGTCCC-3′ 44 584
AAAGGGGGGAGAATAG-3′ 53.2 664
GTTGATCAGAATAAGCG-3′ 55 645
CGAGGAGAGGTATGAA-3′ 55.5 718
TTAGGAGTCAATTTCTATATCT-3′ 52 638
TGAACCTCTATAGCTATAG-3′ 59.1 691
TCCTGAGCGGTTACTTTCGG-3′ 50 399
TATTGCCATTGATCGC-3′ 50 247
TTCAATAGCATTCAACCA-3′ 50 798
TCCTTAATTTTCTTTGTTTGTGAATAAATAGAC-3′ 50 703
TCCTTAATTTTTAGAAAAATCTTCGTTTAAGTA-3′ 50 661
TCTAAGGTTTGATGCCTACAA-3′ 50 774
. or Commons et al.
Table 2 Distribution of superantigens by emm type
Total
(N = 77)
emm1
(N = 25)
emm12
(N = 40)
emm66
(N = 12)
P-value
speA 32 (42%) 25 (100%) 1 (3%) 6 (50%) p < .001
speC 33 (43%) 0 33 (83%) 0 p < .001
speG 77 (100%) 25 (100%) 40 (100%) 12 (100%)
speH 28 (36%) 0 22 (55%) 6 (50%) p < .001
speI 48 (62%) 4 (16%) 37 (93%) 7 (58%) p < .001
speJ 11 (14%) 9 (36%) 1 (3%) 1 (8%) p < .001
speK 0 0 0 0
speL 0 0 0 0
speM 4 (5%) 1 (4%) 3 (8%) 0
ssa 6 (8%) 1 (4%) 4 (10%) 1 (8%)
smeZ 76 (99%) 25 (100%) 40 (100%) 11 (92%)
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ate a positive control for speL.
Literature review
To the best of our knowledge, we included all studies in
our literature review that tested for the presence or ab-
sence of the GAS superantigen genes that showed vari-
ability in our study. These superantigens are speA, speC,
speI, speJ, speM, and ssa. We excluded any studies inTable 3 Superantigen genotype and distribution across emm
Genotype speA speC speG speH speI speJ speK speL spe
A (n = 1) X X X X
B (n = 17) X X
C (n = 1) X X X
D (n = 7) X X X
E (n = 3) X X X
F (n = 1) X X X X
G (n = 1) X X X X
H (n = 2) X X X X
J (n = 19) X X X X
K (n = 3) X X
M (n = 2) X X X X X
N (n = 8) X X X
O (n = 1) X X X X X
P (n = 1) X
Q (n = 4) X X X
R (n = 1) X X X X X
S (n = 1) X X X
T (n = 1) X X X X
U (n = 2) X X X
V (n = 1) X X X X
Superantigen genotypes B and D were found significantly more often in emm type
type 12 isolates. P-values were generated with the two-sided Fisher’s exact test.which superantigen genotypes of individual isolates could
not be determined.
Data analysis
The associations between superantigens and categor-
ical variables were analyzed by Fisher’s two-sided exact
test. STATA (StataCorp, Version 10) was used for all
analyses.
Results and discussion
Distribution of superantigen genes
We identified speA, speC, speG, speH, speI, speJ, speM,
ssa, and smeZ gene sequences from at least one isolate.
We did not find any isolates with speK or speL in the
collection (Table 2). The most common gene, speG, was
present in all isolates. The smeZ gene was present in
99% of 77 isolates. The least common superantigen
genes that were identified in at least one strain were
speM, found in 5% isolates, and ssa, found in 8%
isolates.
The speA genes in emm 1 strains were identified by
the Maripuu et al. speA 1–3, 6 primers. The speA genes
in emm 12 and emm 66 strains were identified by the
Maripuu et al. speA-4, 5 primers, indicating they were
different alleles. The prevalence of superantigen genes
varied across emm type (Table 2). The speA gene wastype
M ssa smeZ emm12 (40) emm1 (25) emm66 (12) p-value
X 0 1 (4%) 0
X 0 13 (52%) 4 (33.3%) <.001
X X 0 1 (4%) 0
X 0 7 (28%) 0 <.001
X 0 2 (8%) 1 (8.3%)
X 0 1 (4%) 0
X 1 (2.5%) 0 0
X X 2 (5%) 0 0
X 19 (47.5%) 0 0 <.001
X 3 (7.5%) 0 0
X 2 (5%) 0 0
X 5 (12.5%) 0 3 (25%)
X 1 (2.5%) 0 0
X 0 0 1 (8.3%)
X 4 (10%) 0 0
X 1 (2.5%) 0 0
X X 1 (2.5%) 0 0
0 0 1 (8.3%)
X X 1 (2.5%) 0 1 (8.3%)
X 0 0 1 (8.3%)
1 isolates. Superantigen genotype J was found significantly more often in emm
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lates, and in only 3% of emm 12 isolates (p < .001). SpeC
was found in 83% of emm 12 isolates and in no emm 1
or emm 66 isolates (p < .001). The speH gene was found
in 55% of emm 12 isolates, 50% of emm 66 isolates, andTable 4 Previously reported superantigen genotypes
Genotype speA speC speG speH speI speJ speK speL sp
A (n = 1) X X X
B (n = 17) X X
C (n = 1) X X X
D (n = 7) X X X
E (n = 3) X X X
F (n = 1) X X X X
G (n = 1) X X X
H (n = 2) X X X X
J (n = 19) X X X X
K (n = 3) X X
M (n = 2) X X X X
N (n = 8) X X X
O (n = 1) X X X X X
P (n = 1) X
Q (n = 4) X X X
R (n = 1) X X X X X
S (n = 1) X X X
T (n = 1) X X X X
U (n = 2) X X X
V (n = 1) X X X X
Previously published emm 1, 12 and 66 superantigen genotypes were reviewed and
paper. “Other name” refers to pattern name given in previously published work. Citin no emm 1 isolates (p < .001). The speI gene was found
in 93% of emm 12 isolates, 58% of emm 66 isolates, and
in 16% of emm 1 isolates (p < .001). The speJ gene was
found in 3% of emm 12 isolates, 8% of emm 66 isolates,
and in 36% of emm 1 isolates (p < .001).eM ssa smeZ Othername Countries emm Year
X X None
X R Australia 1 2001-2002 [6]
A Sweden 1 1989 [15]
X X F Australia 1 2001-2001 [6]
X D Australia 1 2001-2002 [6]
C Sweden 1 1988-2001 [15]
Not Given Norway 1 2006-2007 [16]
Not Given New Zealand 1 Not given [17]
Not Given Spain 1 1999-2003 [18]
I Norway 1 1988-2003 [19]
Not Given Sweden 1 2006-2007 [20]
X None
X None
X X None
X X D China 1 2005-2006 [21]
D China 12 1993-1994,
2005-2006 [21]
X H Australia 12 2001-2002 [6]
S3 Sweden 12 1989-1993 [15]
Not Given Norway 12 2006-2007 [16]
Not Given Spain 12 1999-2003 [18]
VII Norway 12 1988-2003 [19]
S26 Sweden 66 1989 [15]
X None
X X None
X J Australia 12 2001-2002 [6]
Not Given Norway 12 2006-2007 [16]
Not Given Spain 12 1999-2003 [18]
AC Sweden 66 1988-1990 [15]
X None
X None
X None
X Not Given ATCC 1 Not given [17]
X X None
Not Given New Zealand 12 Not given [17]
X X T Australia 12 2001-2002 [6]
Not Given Spain 12 1999-2003 [18]
X None
compared to our collection. “Genotype” refers to designations given in this
ations refer to the reference section.
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We examined the diversity of superantigen genotypes
within the same emm type. We were able to distinguish
20 distinct strains of GAS using superantigen genotypes
alone (Table 3). The three emm types we examined in
this study were further divided into 24 distinct genotypes
by the combination of emm typing and superantigen
genotype. We reviewed previously reported emm 1, 12,
and 66 superantigen genotypes and found many geno-
types have been given multiple names. For further refer-
ence, we have included the original citation and
superantigen genotype name from all studies included in
our literature review (Table 4). For the subsequent ana-
lysis all the genotypes names used are from Table 3.
The most common superantigen genotype, J, con-
tained 19 isolates. The second most common genotype,
B, contained 17 isolates. Genotype J was exclusively
found in emm 12, and represented 48% of all emm 12
isolates (p < .001). Genotype B was significantly associ-
ated with emm 1 (p < .001) but was also found in 4 emm
66 isolates. Genotype D was exclusively found in emm 1
isolates (p < .001).
Discussion
In this study speA and speJ were significantly associated
with emm 1. speH and speI were significantly less likely
to be found in emm 1 isolates as compared to the rest of
the collection (Table 2). Previous studies also found that
speA is frequently found in emm type 1 GAS isolates
[6,15,22,23]. We found that superantigen genotype B
and superantigen genotype D comprised the majority of
emm 1 isolates. Genotype B and genotype D differ only
by the presence of speJ in genotype D. Genotype B has
previously been reported in emm 1 isolates from Australia
between 1989 and 2002 [6]. Genotype D has previously
been reported exclusively in emm 1 isolates. These isolates
were collected in Norway, Spain, New Zealand, and
Australia between 1988 and 2003 [6,15,16,18,19].
In this study speC was significantly associated with
emm 12 and was not found in either emm 1 or emm 66
isolates. Previous studies found speC is often found in
emm 12 isolates including isolates from China and Japan
[23,24]. However, in contrast to the results of the
current study, the studies of isolates from China and
Japan have found that speC is also present in the emm1
isolates from these same collections [23,24].
In the current study, the majority of emm 12 isolates
had superantigen genotype J. Genotype J has previously
been reported in emm 12 and 66 from Norway, Spain,
and Australia between 1989 and 2007, indicating that
this particular genotype is very common and has spread
worldwide [6,15,16,18,19]. There were no statistically
significant associations of superantigens with emm 66.
Only 12 emm 66 isolates were included in this study andthe sample size may have been too small to produce
meaningful results.
Conclusions
Previous studies found superantigens are not randomly
distributed across emm types [6,15,22]. However, associ-
ations between specific superantigens and emm types
often vary by study. Previous studies have suggested nu-
merous hypotheses to explain this variation. It is un-
known if this variation is due to underlying biological
factors that limit the distribution of superantigens, the
selective advantage due to carrying particular superanti-
gens, or the chance expansion of local GAS clones at the
time these studies took place. This is an area of active
research [7,11]. The current study helps to address this
question by reporting the superantigen genotypes of
GAS isolated from a region of the world from which in-
formation on superantigen genotypes is lacking. This is
the first study to report the prevalence of all 11 superan-
tigens in a collection of isolates from South America or
Brazil. Similar to other previously published work we
found some common genotypes of GAS which are
spread world wide as well as novel genotypes of GAS
which have only been reported in this study.
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